Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb 1;39(2):384-385.
doi: 10.1097/HJH.0000000000002722.

Differences between beta-blockers in the treatment of arterial hypertension

Kurt Stoschitzky  1
Affiliations
Comment

Differences between beta-blockers in the treatment of arterial hypertension

Kurt Stoschitzky. J Hypertens. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Thomopoulos C, et al. J Hypertens. 2021 Feb 1;39(2):385. doi: 10.1097/HJH.0000000000002723. J Hypertens. 2021. PMID: 33394864 No abstract available.

Comment on

References

    1. Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertension 2020; 38:1669–1681.
    1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413–2446.
    1. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684–1689.
    1. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of arterial hypertension? A meta-analysis. Lancet 2005; 366:1545–1553.
    1. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J 2004; 25:1341–1362.

MeSH terms

Substances

LinkOut - more resources